Experiences with

Lumacaftor / Ivacaftor

[u]Benefits of ‘transformational’ cystic fibrosis drug highlighted in new review.[/u] A new systematic review by University of Liverpool researchers highlights the positive impact that triple-combination therapy has on the wellbeing of people with Cystic Fibrosis (CF). In August 2020, the European

The rate of discontinuation was considerably higher than previously reported in clinical trials, the authors wrote. https://www.newswise.com/articles/cf-patients-experience-improved-lung-health-with-lumacaftor-ivacaftor-but-with-caveats